Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28486320 | 0.82 | TAAR1 (0.46) | TAAR1L3MBTL1MEN1KDM4AALDH1A1 | |
| SCHEMBL2886009 | 0.78 | TAAR1 (0.43) | TAAR1L3MBTL1MEN1KDM4AALDH1A1 | |
| SCHEMBL4966257 | 0.78 | CA1 (0.50) | TAAR1L3MBTL1MEN1KDM4AALDH1A1 | |
| SCHEMBL5424489 | 0.78 | MEN1 (0.44) | TAAR1L3MBTL1MEN1KDM4AALDH1A1 | |
| SCHEMBL11173252 | 0.77 | TAAR1 (0.42) | TAAR1L3MBTL1MEN1KDM4AALDH1A1 | |
| SCHEMBL14562431 | 0.77 | L3MBTL1 (0.43) | TAAR1L3MBTL1MEN1KDM4AALDH1A1 | |
| SCHEMBL24425806 | 0.74 | MEN1 (0.41) | TAAR1L3MBTL1MEN1KDM4AALDH1A1 | |
| SCHEMBL27679712 | 0.69 | DRD2 (0.40) | TAAR1L3MBTL1MEN1KDM4AALDH1A1 | |
| SCHEMBL28476293 | 0.68 | MME (0.40) | TAAR1SLC6A2SLC6A3SLC1A3SLC1A2 | |
| SCHEMBL9357255 | 0.68 | TAAR1 (0.56) | TAAR1L3MBTL1MEN1KDM4AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | US | claimed |
| EP-1383748-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002051983-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-07-04 | — | — | WO | claimed |
| US-7091360-B2 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AVENTIS PHARMA S.A. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060135781-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AVENTIS PHARMACEUTICALS, INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1495007-A4 | PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES | AXYS PHARM INC (US) | 2006-05-03 | — | — | EP | disclosed |
| EP-1495007-A1 | PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES | AXYS PHARMACEUTICALS, INC. (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20040019218-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | AXYS PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003087068-A1 | PROCESS FOR PREPARING HETEROARYL AND UNSATURATED HETEROCYCLOALKYLMAGNESIUM REAGENTS AND USES | AXYS PHARMACEUTICALS, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049594-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | TAAR1 4546/4885L3MBTL1 4113/4885MEN1 4485/4885 |
| US-20040019218-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | SPINT2, CTSV, CTSZ | TAAR1 4308/4885L3MBTL1 2594/4885MEN1 979/4885 |
| US-20060135781-A1 | Process for preparing heteroaryl and unsaturated heterocycloalkylmagnesium reagents and uses thereof | SPINT2, CTSV, CTSZ | TAAR1 4308/4885L3MBTL1 2594/4885MEN1 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.